An update on autoantibodies in scleroderma
- PMID: 30148799
- PMCID: PMC6546089
- DOI: 10.1097/BOR.0000000000000550
An update on autoantibodies in scleroderma
Abstract
Purpose of review: New research continues to provide important insights into the utility of antibody specificities. This review provides an update of recent findings, and the important insights they provide into disease mechanism.
Recent findings: A growing number of autoantibodies have been discovered in scleroderma patients with unique clinical associations. A subgroup of these antibodies may have functional consequences and contribute to disease pathogenesis, driving the vascular and fibrotic phenotype. Recent research into the relationship between malignancy and scleroderma onset provides important new insights into disease mechanism, and highlights the utility of autoantibodies as unique research probes.
Summary: Continued advances in the study of scleroderma antibody specificities has led to important insights into disease pathogenesis and clinical subgrouping. These advances include newly described specificities, functional antibodies and an emerging understanding of the cancer-scleroderma relationship.
Similar articles
-
Update on autoantibodies in systemic sclerosis.Curr Opin Rheumatol. 2007 Nov;19(6):580-91. doi: 10.1097/BOR.0b013e3282e7d8f9. Curr Opin Rheumatol. 2007. PMID: 17917539
-
Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies.Curr Opin Rheumatol. 2003 Nov;15(6):778-84. doi: 10.1097/00002281-200311000-00016. Curr Opin Rheumatol. 2003. PMID: 14569210 Review.
-
Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance.Curr Opin Rheumatol. 2004 Nov;16(6):723-32. doi: 10.1097/01.bor.0000144760.37777.fa. Curr Opin Rheumatol. 2004. PMID: 15577611 Review.
-
Is scleroderma an autoantibody mediated disease?Curr Opin Rheumatol. 2006 Nov;18(6):579-81. doi: 10.1097/01.bor.0000245726.33006.c3. Curr Opin Rheumatol. 2006. PMID: 17053501 Review.
-
Pathogenic autoantibodies in systemic sclerosis.Curr Opin Immunol. 2007 Dec;19(6):640-5. doi: 10.1016/j.coi.2007.11.004. Curr Opin Immunol. 2007. PMID: 18083509 Review.
Cited by
-
Mapping of the Antinuclear Autoantibodies in Sudanese patients infected with Human Immunodeficiency Virus after HAART receiving: A cross-sectional study.Sci Rep. 2025 Jul 2;15(1):23367. doi: 10.1038/s41598-025-06389-9. Sci Rep. 2025. PMID: 40604026 Free PMC article.
-
Pathogenesis of autoimmune disease.Nat Rev Nephrol. 2023 Aug;19(8):509-524. doi: 10.1038/s41581-023-00720-1. Epub 2023 May 10. Nat Rev Nephrol. 2023. PMID: 37165096 Free PMC article. Review.
-
IP-to-MS: An Unbiased Workflow for Antigen Profiling.J Proteome Res. 2025 Feb 7;24(2):795-812. doi: 10.1021/acs.jproteome.4c00837. Epub 2025 Jan 15. J Proteome Res. 2025. PMID: 39814365 Free PMC article.
-
The Past, Present, and Future in Antinuclear Antibodies (ANA).Diagnostics (Basel). 2022 Mar 7;12(3):647. doi: 10.3390/diagnostics12030647. Diagnostics (Basel). 2022. PMID: 35328200 Free PMC article. Review.
-
Immunogenetics of Systemic Sclerosis.Genes (Basel). 2024 May 5;15(5):586. doi: 10.3390/genes15050586. Genes (Basel). 2024. PMID: 38790215 Free PMC article. Review.
References
-
- Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A. (2014). Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 10;343(6167):152–7. doi: 10.1126/science.1246886. Epub 2013 Dec 5. - DOI - PMC - PubMed
-
Seminal paper providing evidence that scleroderma in a subgroup of RNApol3-positive patients results from the immune system’s response to the cancer. Studying cancers in scleroderma patients, genetic alterations were discovered in the POLR3A locus of cancers in RNApol3-positive patients but not RNApol3 negative, suggesting the autoimmune disease may be initiated by exposure to foreign antigens that cross-reactive with endogenous molecules.
-
- Lazzaroni M-G, Cavazzana I, Colombo E, Dobrota R, Hernandez J, Hesselstrand R, … Airò P (2017). Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. The Journal of Rheumatology, 44(5), 639–647. 10.3899/jrheum.160817 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials